Aminoglycosides plus beta-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactions

The American Journal of Medicine

Volumn 80, Issue 6 SUPPL. 2, 1986, Pages 126-137

  Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZLOCILLIN; AZTREONAM; BETA LACTAM; CARBENICILLIN; CEFOPERAZONE; CEFOTAXIME; CEFSULODIN; CEFTAZIDIME; CEFTRIAXONE; GENTAMICIN; LATAMOXEF; NETILMICIN; TOBRAMYCIN;

ABSTRACT REPORT; DRUG EFFICACY; DRUG INTERACTION; DRUG MIXTURE; DRUG RESISTANCE; DRUG THERAPY; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVEY; THERAPY;

AMIKACIN; AMINOGLYCOSIDES; ANIMAL; ANTIBIOTICS; ANTIBIOTICS, LACTAM; CEPHALOSPORINS; COMPARATIVE STUDY; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; GENTAMICINS; GRAM-NEGATIVE BACTERIA; HUMAN; MICROBIAL SENSITIVITY TESTS; NETILMICIN; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 0022477642     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(86)90490-0     Document Type: Article

References (90)

1. Synergism between amikacin and cefazolin against Klebsiella
2. Clinical significance of in vitro synergism between antibiotics in gram-negative infections
3. Significance of antimicrobial synergism for the outcome of gram-negative sepsis
4. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trial
5. Review of clinical significance of synergy in gram-negative infections at the University of California Los Angeles Hospital
6. Antimicrobial synergism in the therapy of gram-negative rod bacteremia
7. Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin
8. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis
9. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats
10. Therapy in neutropenic rats infected with Pseudomonas aeruginosa
11. Emergence of gentamicin and carbenicillin-resistant Pseudomonas aeruginosa in a hospital environment
12. Endemic aminoglycoside resistance in gram-negative bacilli: epidemiology and mechanisms
13. Emergence of aminoglycoside multiresistant Pseudomonas aeruginosa in 1982–1983: mechanisms of resistance and epidemiology in a general hospital
14. Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin
15. Inactivation of aminoglycosides by penicillins
16. Stability of gentamicin, tobramycin and amikacin in combination with four beta-lactam antibiotics
17. In vitro and in vivo interactions of recent cephalosporins with gentamicin and amikacin
18. Antibiotic synergy and antagonism against clinical isolates of Klebsiella species
19. In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic
20. Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins
21. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins
22. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin and ticarcillin alone and in combination with an aminoglycoside
23. Comparative in vitro appraisal of piperacillin including activity against Salmonella typhi
24. Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens
25. Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae
26. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus
27. Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae
28. Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins
29. Antibacterial activity of a new 1-oxo-cephalosporin compared with that of other beta-lactam compounds
30. A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides
31. Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin resistant members of the family Enterobacteriaceae
32. Synergism at clinically attainable concentrations of aminoglycoside and betalactam antibiotics
33. Comparative in vitro activity of Nformimidoyl-thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability
34. An outbreak of nosocomial infection due to multiply resistant Serratia marcescens, evidence of interhospital spread
35. Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides
36. In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics
37. The comparative synergistic activity of amikacin, gentamicin, netilmicin and azlocillin, mezlocillin and ticarcillin against S. marcescens
38. Comparative activity of tobramycin, amikacin and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa
39. The carbenicillingentamicin combination against Pseudomonas aeruginosa
40. Susceptibility of Pseudomonas aeruginosa to tobramycin or gentamicin alone and combined with carbenicillin
41. Bacteriostatic and bactericidal activities of beta-lactam antibiotics enhanced by the addition of low concentration of gentamicin
42. Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia
43. In vitro activity synergism and testing parameters of amikacin, with comparison to other aminoglycoside antibiotics
44. Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa
45. Comparative synergistic activity of cefoperazone cefotaxime moxalactam and carbenicillin combined with tobramycin against Pseudomonas aeruginosa
46. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity interaction index and killing curve method
47. Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas
48. Effect of calcium, magnesium and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa
49. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
50. Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli
51. In vitro studies with aztreonam
52. Evaluation of aztreonam in “difficult to treat” infections with prolonged post-treatment follow-up
53. Aztreonam: the first monobactam
54. Current state of infectious diseases
55. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections
56. In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients
57. In vitro activities of aztreonam, piperacillin and ticarcillin, combined with amikacin against amikacin resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis
58. In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli
59. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa
60. In vitro evaluation of N-formimidoyl-thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus
61. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model
62. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients
63. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer
64. Empiric antibiotic therapy
65. Comparative effectiveness of combinations of amikacin and penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial
66. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin
67. Therapeutic implications of interaction of gentamicin and penicillins
68. Combined use of gentamicin and carbenicillin
69. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin
70. Biological aspects of the interaction between gentamicin and carbenicillin
71. Interactions of carbenicillin and ticarcillin with gentamicin
72. Inactivation of gentamicin by penicillins in patients with renal failure
73. Gentamicin and ticarcillin serum levels
74. Interactions between aminoglycoside antibiotics and carbenicillin or ticarcillin
75. Factors influencing the inactivation of aminoglycosides by beta-lactams
76. Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin or amikacin and carbenicillin or ticarcillin
77. Comparative aminoglycoside inactivation by beta-lactam antibiotics
78. Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions
79. Effects of carbenicillin on aminoglycoside serum half life in hemodialysis patients
80. Effect of concentration and time upon inactivation of tobramycin gentamicin netilmicin and amikacin by azlocillin carbenicillin mecillinam mezlocillin and piperacillin
81. Studies on the inactivation of aminoglycoside antibiotics by acylureidopenicillins and piperacillin
82. Stability of gentamicin, tobramycin and amikacin in combination with four beta-lactam antibiotics
83. Stability of gentamicin and cefamandole in serum
84. Selective inactivation of aminoglycosides by newer beta-lactam antibiotics
85. Roles of ribosomal binding, membrane potential and electron transport in bacterial uptake of streptomycin and gentamicin
86. Penetration of the outer membrane of Pseudomonas aeruginosa by synergistic combinations of beta-lactam and aminoglycoside antibiotics
87. Antimicrobial combination in the therapy of infections due to gram-negative bacilli
88. Combinations of antibiotics for therapy of severe infections in cancer patients
89. Moxalactam plus piperacillin or moxalactam plus amikacin
90. Comparative efficacy and toxicity of moxalactam/piperacillin versus moxalactam/amikacin in febrile granulocytopenic patients